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Abstract 32 
Background: Any reduction in myocardial oxygen delivery relative to its demands can 33 
impair cardiac contractile performance. Understanding the mitochondrial metabolic 34 
response to hypoxia is key to understanding ischemia tolerance in the myocardium. 35 
We employed a novel combination of two genome-scale methods to study key 36 
processes underlying human myocardial hypoxia tolerance. In particular, we 37 
hypothesised that computational modelling and evolution would identify similar 38 
genes as critical to human myocardial hypoxia tolerance. Methods & Results: We 39 
analysed a reconstruction of the cardiac mitochondrial metabolic network using 40 
constraint-based methods, under conditions of simulated hypoxia. We used flux 41 
balance analysis, random sampling and principle components analysis to explore 42 
feasible steady-state solutions. Hypoxia blunted maximal ATP (-17%) and haeme (-43 
75%) synthesis and shrank the feasible solution space. TCA and urea cycle fluxes 44 
were also reduced in hypoxia, but phospholipid synthesis was increased. Using 45 
mathematical optimization methods, we identified reactions that would be critical to 46 
hypoxia tolerance in the human heart. We used data regarding SNP frequency and 47 
distribution in the genomes of Tibetans (whose ancestors have resided in persistent 48 
high-altitude hypoxia for several millennia). Six reactions were identified by both 49 
methods as being critical to mitochondrial ATP production in hypoxia: 50 
phosphofructokinase, phosphoglucokinase, Complex II, Complex IV, aconitase and 51 
fumarase. Conclusions: Mathematical optimization and evolution converged on 52 
similar genes as critical to human myocardial hypoxia tolerance. Our approach is 53 
unique and completely novel and demonstrates that genome-scale modelling and 54 
genomics can be used in tandem to provide new insights into cardiovascular genetics. 55 
 3 
Introduction 56 
Systems biology uses mathematical and computational methods to describe and 57 
explore complex biological networks. An important recent trend in systems biology 58 
has been the development and application of ‘constraint-based modelling’ 1. 59 
Constraint-based modelling provides three very significant advantages over traditional 60 
mathematical approaches for the study of large and complex biochemical systems. 61 
First, very large models (up to thousands of reactions) can be accommodated. Thus 62 
the entire metabolic network of a mitochondrion (for example) can be modelled. 63 
Second, precise descriptions of the behaviour of each enzyme in the system (i.e. rate 64 
laws) are not required. Finally, detailed information regarding the activity of a single 65 
protein (for example, whether an enzyme is allosterically modified or not) is not 66 
necessary. Thus unlike traditional ‘kinetic’ models, constraint-based models do not 67 
rely on, nor do they require, detailed knowledge of an enzyme’s phosphorylation 68 
status (for example), nor the abundance of substrates and products.  69 
 70 
Constraint-based modelling is able to confer these advantages because the underlying 71 
models and assumptions are simple. The basic unit for constraint-based modelling is a 72 
network model, similar to the London Underground map. In the case of a biochemical 73 
network, this is constructed using 1) the known presence or absence of reactions 74 
based on genomic, proteomic or biochemical data; and 2) the known (species-75 
specific) stoichiometry of all the chemical reactions included in the network. To this 76 
basic model are added a series of ‘constraints’ (from which the method derives its 77 
name), including reaction directionality, mass and charge balancing and absolute 78 
limits to metabolite uptake and excretion. Unlike traditional enzyme kinetic 79 
parameters (e.g. Michaelis-Menten midpoints), many of the underlying assumptions 80 
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in constraint-based models are robust to variations in physical environment (such as 81 
temperature). However, constraint-based models are not able to simulate the exact 82 
behaviour of a biochemical system. Instead, by keeping the underlying assumptions as 83 
simple and robust as possible, they attempt to mirror the constraints which the true 84 
network faces in vivo. Nevertheless, one can predict the most likely behaviour of the 85 
system (using Monte Carlo methods) or predict the behaviour of the network at an 86 
optimum value of some assumed ‘physiological objective’. A more detailed 87 
description of the approach can be found in the Methods and Supplemental Materials 88 
of the present manuscript, and in many excellent reviews 1-4. Regarding its utility: 89 
constraint-based modelling, using genome-scale metabolic networks, has been used to 90 
successfully predict the metabolic signatures of human inherited diseases 5-8, and to 91 
permit the in silico design of tumour-specific toxins 9 and aid in the design of 92 
microbial strains for the purposes of metabolic engineering 10.  93 
 94 
Myocardial ischemia and hypoxia, whether cause or consequence, are common 95 
features of the failing heart; understanding the mitochondrial response to hypoxia is 96 
key to understanding ischemia tolerance. Myocardial hypoxia can be due to any 97 
number of factors, but is most commonly caused by coronary artery or microvascular 98 
heart disease, exacerbated by increased oxygen demand from ventricular remodelling. 99 
Ischaemic heart disease remains the leading cause of death in the developed world; 100 
therefore gaining new insights into the mechanisms whereby heart cells can survive 101 
hypoxia of any duration is a matter of considerable importance.  102 
 103 
Hypoxia, consequent upon a reduction in barometric pressure, is also a consistent 104 
environmental challenge for human populations at high altitude, where it has led to a 105 
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robustly detectable degree of genetic and phenotypic divergence over evolutionary 106 
timescales 11, 12. Thus human populations at high altitude offer a unique opportunity to 107 
study the genetic response to hypoxia. We used a novel combination of genome-scale 108 
modelling, mathematical optimization and genome-wide analysis of single nucleotide 109 
polymorphisms (SNPs) in humans to study the response of cardiac mitochondria to 110 
hypoxia. In particular, we sought to test our hypothesis that if evolution is an 111 
optimization process, then mathematical optimization methods, when applied to a 112 
metabolic model, would converge on the same set of reactions, critical to 113 
environmental (in this case hypoxic) performance. By comparing information from 114 
natural (evolution) and mathematical optimization methods we sought to identify key 115 
genes and reactions that underlie cardiac tolerance to hypoxia.  116 
  117 
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Methods 118 
The reconstruction of the human cardiac mitochondrial metabolic network from 119 
proteomic and biochemical data was described previously 13. Briefly, proteomic and 120 
transcriptomic data were used to derive an organelle ‘metabolic parts list’ (i.e. a list of 121 
all metabolic proteins known to be associated with a cardiac mitochondrion). These 122 
parts were ‘connected’ by their species-specific stoichiometric chemical equations. 123 
The draft reconstruction was extensively tested and manually curated. The final model 124 
used herein comprised 195 reactions, 235 metabolites and 25 exchange reactions (for 125 
a full description see 13, 14 and the Supplementary Materials). The exchange reactions 126 
did not represent genuine biochemical reactions, but instead described the exchanges 127 
that were necessary between the network and its environment so that a steady-state 128 
could be achieved. Having reconstructed the network, a series of limits or ‘constraints’ 129 
were added, all of which constrained the upper and lower limits of metabolite 130 
exchange of the model with its environment (e.g. oxygen, glucose). These constraints 131 
are in Supplementary Table 1 and represent maximum and minimum flux rates in 132 
human heart mitochondria in vivo. To simulate hypoxia, we reduced the upper 133 
constraint on oxygen uptake in the model to 25% of baseline values (normoxia), from 134 
39.1 μM min-1 (g mitochondrial protein)-1 (henceforth shortened to U) to 9.775 U. Our 135 
choice of simulating severe hypoxia was motivated by an intention to highlight any 136 
effects; however, it is worth noting that complete anoxia can occur in regions of 137 
ischemic myocardium (e.g. during acute myocardial infarction).  138 
 139 
Computational analysis of network models rarely leads to a single set of predicted 140 
fluxes. Instead, methods are used to analyze the possible combinations of fluxes that 141 
allow a steady-state, given the applied constraints. The solutions together are termed 142 
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the feasible steady-state solution space. Alternatively, one can use linear optimization 143 
to compute a set of fluxes that optimize the value of a given objective function, an 144 
approach typically referred to as flux balance analysis (FBA). For example, this 145 
method would return a set of fluxes that correspond to the highest possible rate of 146 
ATP production by the network, if ATP production was the objective function. When 147 
conducting FBA, we optimized the mitochondrial network for three objective 148 
functions (phospholipid, haeme and ATP synthesis) 13. Alternate optimal solutions 149 
(i.e. other sets of fluxes that also gave an optimal objective) were accounted for via 150 
flux variability analysis (see below). We also studied the optimization of all three 151 
objectives simultaneously (see Supplementary Materials for details). This method 152 
comprises placing the objective functions under study into hierarchical order (for 153 
example, haeme biosynthesis then phospholipid biosynthesis then ATP synthesis). 154 
The network is optimized for the first objective, then optimized for the second with 155 
the first held at optimal value and so forth.  156 
 157 
We used two computational methods to identify reactions that are critical to hypoxia 158 
tolerance in the mitochondria metabolic network – shadow prices 15 and flux spans 16. 159 
Shadow prices have been used in metabolic network analysis before 15, 17. Shadow 160 
prices (also known as Lagrange multipliers) are measures of the degree to which the 161 
value of the objective function is affected by the availability of a particular resource. 162 
For example, if ATP synthesis were the objective function, a shadow price of 1.0 for 163 
glucose (for example) would indicate that a 1 unit increase in glucose availability 164 
would lead to an equivalent increase in ATP synthesis. A shadow price of 2.0 would 165 
indicate that a unit increase in the availability of glucose would result in a two unit 166 
increase in ATP synthesis, and so forth. We reasoned therefore that reactions for 167 
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which metabolites with large, positive shadow prices were either substrates or 168 
products, would be crucial to hypoxic performance (at least, for the objective function 169 
under investigation). To assess the likelihood that our method had outperformed 170 
chance, we used simple permutation testing.  171 
 172 
Our second approach was to use flux spans. Using flux variability analysis 18 we 173 
computed the range of values that flux through each reaction could take at an 174 
optimum (computed using FBA). Taken together, these ranges delineate the set of 175 
alternate optimal solutions (i.e. different sets of fluxes that result in the same optimal 176 
value of the objective) 18. By calculating the difference between the upper and lower 177 
feasible fluxes we derived a flux span for each reaction. Here we express these as a 178 
relative ratio. Hence a reaction with flux = 10 U and with the lower and upper feasible 179 
fluxes being 8 and 12 U respectively would have a relative flux span of 0.4 (or 40%). 180 
We reasoned that reactions with the smallest relative flux spans would be critical to 181 
hypoxia tolerance and hypoxic performance. Again, we used permutations to estimate 182 
the probability that our method had outperformed chance alone.  183 
 184 
We used data from a genome-wide allelic differentiation scan (GWADS) comparing 185 
SNP frequencies of Tibetans (n = 35) residing at 3200-5000 m, with 84 individuals 186 
from the founder population. Subjects were recruited from three distinct regions of 187 
China: the North Western region of Yunnan province, Mag Xiang and Zhaxizong 188 
Xiang (both in the Tibet Autonomous Region). Genotypic data from the HapMap 189 
Phase III Han population were also included. These data have been analyzed 190 
previously11 and full details can be found in this earlier publication. Each gene was 191 
assigned a genome-wide p-value that serves as an estimate of the degree of selective 192 
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pressure applied to that gene (through differences in SNP frequency). Details 193 
regarding the calculation of these p-values can also be found elsewhere 11. We 194 
extracted the p-values corresponding to the genes in our model and ranked genes by 195 
smallest GWADS p-value first, producing a list of nuclear-encoded mitochondrial 196 
genes with an accompanying measure of selective pressure in humans living in 197 
persistent hypoxia.  198 
 199 
Where appropriate, means and standard deviations are given. However, modelling 200 
results are often a single datum point (e.g. differences in optimal ATP synthesis rate, 201 
determined using flux balance analysis, under hypoxia and normoxia) and are 202 




Results  206 
We optimized the network for three physiological ‘targets’ (objective functions) - 207 
ATP, haeme and phospholipid biosynthesis 13 – using flux balance analysis (FBA) 1. 208 
Hypoxia reduced the optimal ATP synthesis rate by 13%, from 45.8 to 36.6 U. Figure 209 
1 shows a quantized heatmap of the accompanying differences in flux. There were 210 
reductions in flux through many reactions comprising the TCA cycle and oxidative 211 
phosphorylation. There were also reductions in flux through most reactions 212 
comprising fatty acid uptake, transport, activation and oxidation, although some were 213 
maintained due to the imposition of a minimum uptake rate (this is a physiological 214 
constraint imposed by the ability of fatty acids to diffuse freely across membranes). 215 
Glycolytic rates were similar, which was expected as maximal ATP synthesis was the 216 
objective. The flux through multiple reactions required for phospholipid biosynthesis 217 
were increased and the demand reaction was activated in hypoxia. To ensure that the 218 
degree of simulated hypoxia affected our results quantitatively but not qualitatively, 219 
we performed additional flux balance analysis experiments at various intermediate 220 
oxygen uptake rates. The results are in Supplementary Figure 1. Briefly, maximal 221 
ATP synthesis was progressively reduced by increasing hypoxia. Consistent with our 222 
interpretation, phospholipid biosynthesis was not activated until O2 uptake dropped 223 
below a critical level, at which point a ‘sink’ for fatty acid carbons was required. 224 
There was no evidence of qualitative shifts in carbon flux as maximal O2 uptake rate 225 
was progressively reduced. 226 
 227 
Haeme synthesis was blunted by 75% in hypoxia (hypoxia: 0.650 vs. normoxia: 2.44 228 
U). The pattern of flux differences between the optimized network in normoxia and 229 
hypoxia was similar to that with ATP synthesis as the objective. Flux through 230 
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reactions comprising the TCA cycle, oxidative phosphorylation, the urea cycle and 231 
haeme synthesis itself were suppressed. There were increases in long-chain (C20:4 232 
and C22:6) activation and an increase in phospholipid biosynthesis. A heatmap of 233 
differences in flux across the network under these conditions (haeme biosynthesis as 234 
the objective function in hypoxia vs. normoxia) is given in Supplementary Figure 2. 235 
However, when phospholipid biosynthesis was the objective it was unchanged by 236 
oxygen restriction, at 22.8 U.  237 
 238 
We then performed multiple objective analyses with three different hierarchies of 239 
objective functions. 1. ATP > haeme > phospholipid: In normoxia, and with ATP 240 
synthesis fixed at its optimal value of 45.8 U, haeme and phospholipid synthesis were 241 
eliminated. In hypoxia, with ATP synthesis fixed at its optimal value of 36.6 U, 242 
haeme synthesis was still eliminated; however, optimized phospholipid biosynthesis 243 
was now non-zero, although reduced ~100-fold at 0.265 U. 2. Haeme > phospholipid 244 
> ATP: In normoxia, with haeme biosynthesis at its optimal rate of 2.44 U, both 245 
phospholipid and ATP synthesis were abolished. In hypoxia, with haeme biosynthesis 246 
at 0.650, phospholipid biosynthesis was possible and optimized to 0.867 U; ATP 247 
synthesis was abolished. 3. Phospholipid > haeme > ATP: As maximal phospholipid 248 
biosynthesis was unaffected by hypoxia it was fixed at 0.867 U for both conditions 249 
(normoxia/hypoxia). In both normoxia and hypoxia, haeme biosynthesis gained 250 
optimal values the same as those where it was the only objective function considered 251 
(normoxia: 2.44 U vs. hypoxia: 0.650 U).  In normoxia, ATP biosynthesis was 252 
subsequently limited to 8.85 U; in hypoxia it was reduced far less, to 19.3 U. A 253 
summary of all the optima is in Supplementary Table 2. 254 
 255 
 12 
We next used uniform random sampling 19, a method that characterizes the steady-256 
state solution space without requiring an objective function. Figure 1b shows a 257 
quantized heatmap of differences in median flux. Consistent with the FBA results, 258 
fluxes through reactions comprising oxidative phosphorylation, the TCA cycle and 259 
fatty acid metabolism were reduced in hypoxia. Without the requirement to maximize 260 
ATP synthesis in normoxia that was elsewhere imposed by FBA, glycolytic flux 261 
increased in hypoxia. The heatmap shows a reduction in flux through lactate 262 
dehydrogenase and the lactate transporter; however, this represents a reversal in flux, 263 
from uptake to efflux. Also noteworthy is a reduction in urea cycle flux in hypoxia. 264 
 265 
We analysed the sampled data using principal components analysis (PCA), allowing 266 
us to visualize patterns of change. We modelled the sampled data together and found 267 
that five components captured 65% of the total variance. When plotted, the scores on 268 
these components revealed that hypoxia substantially reduced the dimensions of the 269 
solution space, reducing the flexibility of the metabolic network even though the 270 
dimensions of the space were the same. This was especially apparent in principal 271 
components 1 and 2 (Figure 2), with principal component 1 being dominated by 272 
reactions related to gas exchange, the TCA cycle and oxidative phosphorylation and 273 
principal component 2 being dominated by reactions related to iron transport and 274 
haeme biosynthesis.  275 
 276 
Given that optimal phospholipid biosynthesis was unaffected by oxygen restriction, 277 
we continued by studying those metabolites and reactions that limited optimal ATP 278 
and haeme biosynthesis in the mitochondrial metabolic network under hypoxia. We 279 
first computed shadow prices for all metabolites in the model when optimising the 280 
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network for either ATP or haeme synthesis. Table 2 gives metabolites with the largest 281 
positive shadow prices and the corresponding twenty discrete reactions for each 282 
objective function. Three classes of metabolite (and reaction) dominated: long-chain 283 
(>20C) fatty acid transport, glycolysis and haeme biosynthesis. When optimising for 284 
ATP synthesis, the largest shadow prices were several-fold larger than when 285 
optimising for haeme synthesis (e.g. 4.0 for cytosolic fructose diphosphate, fdp(c), vs. 286 
1.2 for cytosolic arachidonic acid, c206(c)). When optimizing the network with ATP 287 
synthesis as the objective function, the metabolites with large positive shadow prices 288 
were mainly related to glycolysis, oxidative phosphorylation and the TCA cycle. 289 
 290 
We next computed flux spans, using flux variability analysis. The reactions with the 291 
smallest relative flux spans when optimizing the network for either haeme or ATP 292 
synthesis are given in Table 3. As with shadow prices, the magnitude of the parameter 293 
(in this case, relative flux span) was several fold different when optimizing ATP vs. 294 
haeme synthesis; in both cases the difference (larger shadow prices and smaller flux 295 
spans) was consistent with ATP synthesis being more tightly restricted by hypoxia. 296 
Interestingly, reactions related to oxidative phosphorylation both had narrow flux 297 
spans regardless of whether ATP or haeme synthesis were the objectives. In particular, 298 
complex IV of the respiratory chain was ranked in the top two (Table 3). Perhaps 299 
unsurprisingly, reactions related to proto-haeme synthesis and iron transport also had 300 
small relative flux spans when optimizing for haeme synthesis. When optimizing the 301 
network for ATP synthesis, reactions from the TCA cycle and glycolysis were highly 302 
represented. 303 
 304 
We generated a complete list of nuclear-encoded mitochondrial genes with a 305 
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corresponding measure of selective pressure at high altitude. The twenty ‘most 306 
selected’ genes (i.e. smallest p-value) are in Table 1. Using permutations, we assessed 307 
the likelihood that mathematical optimization had outperformed chance when 308 
predicting genes under pressure. When conducting shadow price analysis with ATP 309 
synthesis as the objective, we selected the 16 metabolites with the largest positive 310 
shadow price corresponding to 20 discrete reactions shown in Table 2. Of these 20 311 
reactions, two (phosphofructokinase (PFK) and phosphoglycerate kinase (PGK)) 312 
carried flux and corresponded to genes in Table 1. However, permutation testing 313 
suggested that random selections of 16 metabolites would equal or outperform our 314 
modelling approach most of the time (p = ~0.860). We observed that two of the only 315 
three metabolites with shadow prices of 3 or greater when optimizing the network for 316 
either objective (cytosolic fructose 6-phosphate and fructose diphosphate, f6p(c) and 317 
fdp(c) respectively in Table 2) are both substrate and product for PFK, the most 318 
‘heavily selected’ gene in Table 1. We next compared the reactions highlighted by 319 
shadow price analysis whilst optimizing the network for haeme synthesis. Three 320 
reactions were common with those in Table 1: hydroxymethylbilane synthase 321 
(HMBS), porphobilinogen synthase (PPBNGS) and phosphoglycerate kinase (PGK). 322 
Once again, permutations suggested that shadow pricing had not outperformed chance 323 
when identifying genes under pressure. 324 
 325 
We used a similar approach to assess the performance of flux span analysis. Table 3 326 
shows that flux span analysis identified three (haeme synthesis) and six (ATP 327 
synthesis) reactions that were common with those that were the most heavily selected 328 
genes in Table 1. With ATP synthesis as the objective, we used permutation testing to 329 
assess whether modelling had outperformed chance when predicting genes under 330 
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pressure. Random selections only matched flux span analysis 1675 out of 100000 331 
times, offering evidence that this approach had outperformed chance at p < .05.  332 
 333 
We repeated this process with haeme synthesis as the objective function. Using 334 
100000 permutations, random selection matched the model performance 335 
approximately half the time (p = ~0.525). Hence using flux span analysis with haeme 336 
as the objective had not outperformed chance.337 
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Discussion 338 
Myocardial hypoxia can be either acute or chronic and occurs whenever oxygen 339 
delivery is insufficient to meet the needs of the contracting myocardium. This can be 340 
due to any combination of reduced O2-carrying capacity due to anaemia, reduced 341 
haemoglobin saturation (whether environmental or pathological), poor cardiac output 342 
or compromised blood flow due to coronary artery or microvascular heart disease, and 343 
increased oxygen demand associated with stress or structural remodelling (e.g. 344 
ventricular hypertrophy). Ischaemic heart disease remains the leading cause of death 345 
in the developed world. A notable feature of heart failure is that, once left ventricular 346 
dysfunction has been established, patients suffer a relentless apoptotic loss of viable 347 
cardiomyocytes that some investigators believe to be due to repeated, transient 348 
ischaemic and hypoxic events 20. Therefore understanding the mechanisms whereby 349 
heart cells can survive either transient or sustained hypoxia and ischaemia is a matter 350 
of considerable importance. Here we present an entirely new approach to this question 351 
using systems biology methods that encompass genomics, metabolic modelling and 352 
mathematical optimization. 353 
 354 
We first studied the effect that hypoxia had on the solution space (the set of all 355 
feasible fluxes) of the reconstructed cardiac mitochondrial metabolic network using 356 
two complementary methods – optimization (FBA) and Monte Carlo sampling. 357 
Optimization requires an objective function; in keeping with previous work we 358 
studied three objectives that are central to mitochondrial function: the synthesis of 359 
ATP, haeme and mixed phospholipids 13. Although maximal phospholipid synthesis 360 
was unaffected by hypoxia, both haeme and ATP synthesis were reduced (by 75% and 361 
13% respectively). The reduction in maximal ATP synthesis was accompanied by 362 
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reductions in TCA cycle flux, oxidative phosphorylation and fatty acid uptake and 363 
processing but a seemingly paradoxical increase in phospholipid biosynthesis. 364 
 365 
The degree to which maximal haeme synthesis was blunted in hypoxia was striking. 366 
This 75% loss of proto-haeme synthesis capacity was accompanied by many of the 367 
metabolic features observed when optimizing ATP production in hypoxia. Haeme is a 368 
major component of haemoglobin, itself substantially increased in response to 369 
hypoxia to enhance systemic oxygen transport 21. Thus network stoichiometry forms a 370 
constraint to haeme biosynthesis that may partly define the speed with which haeme 371 
can be synthesized in hypoxia. Non iron-deficient anaemia is a common feature in 372 
heart failure patients, yet its aetiology is unknown 22. Furthermore, many studies have 373 
shown that reduced haemoglobin is an independent predictor of risk in heart failure 374 
patients 23, 24, although again the mechanism remains poorly understood. Our 375 
simulations suggest that hypoxia itself can cause significant reductions in proto-376 
haeme synthesis, both in the heart and elsewhere, and that hypoxia of any kind could 377 
lead to a vicious cycle of blunted haeme synthesis, reduced O2-carrying capacity in 378 
blood and subsequently worsened hypoxaemia. Furthermore, in cultured human 379 
neurons, haeme deficiency causes a decrease in (haeme-containing) complex IV 380 
(cytochorome c oxidase) and activation of nitric oxide synthase 25. Given that 381 
complex IV release is a key component of the p53 apoptotic cascade 26, this suggests 382 
an intriguing new avenue for investigations into hypoxia-induced myocyte apoptosis. 383 
 384 
We studied the effect on mitochondria of forcing them to balance competing 385 
objectives in hypoxia. When ATP production was given hierarchical ‘superiority’ (as 386 
is almost certainly the case in vivo), haeme synthesis was completely abolished in 387 
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normoxia and hypoxia. Thus haeme and ATP synthesis compete for the same 388 
resources; quite moderate reductions in O2 supply, coupled with increases in ATP 389 
demand, might lead to profound reductions in haeme synthesis capacity due to 390 
stoichiometric constraints in the metabolic network. Interestingly, phospholipid 391 
biosynthesis was abolished in normoxia under this hierarchy but was active in 392 
hypoxia. This was likely due to competition with ATP synthesis for lipids; in hypoxia, 393 
ATP synthesis was diminished freeing up lipids for phospholipid synthesis. 394 
 395 
We next studied the set of feasible solutions using random sampling. Multiple random 396 
samples of the solution space allow the generation of probability density functions for 397 
flux through every reaction; the most probable value can often predict the measured in 398 
vivo rate 14. As with linear optimization (FBA) we observed reductions in TCA cycle 399 
and oxidative phosphorylation reactions, in addition to a reduction in urea cycle flux. 400 
This last is intriguing because flux through arginosuccinate synthetase (ASS) was 401 
decreased in simulated hypoxia. ASS been elsewhere been reported as a target of the 402 
von Hippel-Lindau tumour suppressor gene (VHL) 27, an inverse regulator of HIF-1. 403 
Manipulation of VHL expression led to corresponding changes in ASS levels in 404 
RCC10 renal cell carcinoma cells.  405 
 406 
Once again we observed that many of the reactions required for phospholipid 407 
biosynthesis were increased and the biosynthesis reaction itself was activated in 408 
hypoxia. Without this redirection of fatty acid flux, the imposition of hypoxia, 409 
combined with minimum uptake rates for fatty acids, would have led to an 410 
accumulation of unoxidized fatty acids in the model and a loss of homeostasis. 411 
Cardiac mitochondria face an identical challenge in vivo and redirect fatty acids to 412 
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storage (away from oxidation) when ischaemic 28. Similarly, Langendorff-perfused 413 
hearts exposed to acute hypoxia increase phospholipid biosynthesis to maintain lipid 414 
homeostasis 29. We also observed an increase in glycolytic flux (Figure 1B). 415 
 416 
Overall, the pattern of change in metabolic flux in our simulations was strikingly 417 
consistent with experimental observations of cellular responses to hypoxia, including 418 
the reduction in flux through pyruvate dehydrogenase (PDHm) in vivo that is brought 419 
about by modulation of pyruvate dehydrogenase kinase 30. It is interesting to note that 420 
the reduction in flux through PDHm in our simulations directly resulted from network 421 
stoichiometry, without any additional explanation or control. While the notion that 422 
glycolytic flux is increased in hypoxia is certainly not new, altered (particularly 423 
increased) lipid biosynthesis in response to hypoxia is a less often considered 424 
component of hypoxia tolerance. Previous investigators have reported both increased 425 
29, 31 and decreased 32 lipid synthesis in hypoxia in model systems. These 426 
discrepancies may be due to differences in isotope labelling strategy (e.g. acetate vs. 427 
glycerol vs. palmitate) or outcome measure. However, there is no question that lipids 428 
accumulate in the heart in response to hypoxia and ischaemia 28. It should be noted 429 
that the details of whole heart lipid-handling in hypoxia and/or ischemia may be 430 
different to the mitochondrial response considered in isolation. It is interesting also 431 
that lipotoxicity – defined as a chronic mismatch between oversupply of acetyl-CoA 432 
from lipid breakdown and its subsequent mitochondrial oxidation – is a stoichiometric 433 
disorder and can be as readily caused by impaired oxidative phosphorylation (for 434 
example, by hypoxia) as lipid oversupply. The consistency of our simulations with 435 
experimental observations reinforced to us the notion that our methods were both 436 
robust and relevant. 437 
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 438 
We sought to test whether mathematical optimization had converged on the same 439 
reactions that human evolution had identified as being critical to optimal hypoxic 440 
function. We used data from a GWADS scan comparing SNP frequencies of Tibetans 441 
residing at 3500 m (and whose ancestors have ‘lived high’ for over 10,000 years 33) 442 
with individuals from the HapMap Phase III Chinese Han sample, who are closely 443 
related but have resided at sea level throughout 11. Tibetans were ideal for this study 444 
because, despite systemic adjustments (for example, increased breathing rates), they 445 
continue to have lower arterial oxygen content than sea-level dwellers 34. 446 
 447 
It is interesting that the largest shadow prices were recorded when optimizing the 448 
mitochondrial metabolic network for ATP synthesis in hypoxia. This suggests that, 449 
even in the case of competing objectives, increasing the supply of these metabolites 450 
would be especially advantageous when oxygen supply is limited (either by 451 
environment or pathology). The metabolite with the largest shadow price in any 452 
analysis we conducted was fructose diphosphate, a product of phosphofructokinase 453 
(PFK). However, permutation testing failed to support the notion that shadow prices 454 
and evolution had converged on similar reactions. 455 
 456 
The results gained by examining flux spans were more compelling. Flux spans are the 457 
range of values within which a reaction rate can lie at a computed optimum. We 458 
reasoned that reactions with narrow flux spans would be under greater selective 459 
pressure. We generated a list of reactions with the smallest flux spans (yet which 460 
carried flux) and compared these with the SNP data. When we optimized for ATP 461 
synthesis, the results supported the notion that mathematical optimization and 462 
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evolution had converged on similar reactions (where 6/20 reactions were common 463 
between the two selections). The common reactions selected by flux span analysis and 464 
evolution were related to haeme synthesis (although only when optimizing for haeme 465 
synthesis), glycolysis (PFK, PGK), the TCA cycle (aconitase and fumarase) and 466 
oxidative phosphorylation (Complexes II and IV). We propose that our combined 467 
method has identified reactions that are especially important in maintaining or 468 
increasing mitochondrial ATP synthesis in the hypoxic heart. This view is supported 469 
by the existing literature. For example, it was recently reported that mice exposed to 470 
three weeks of normobaric hypoxia had reduced Complex II, IV and aconitase activity 471 
in cardiac mitochondria 35 while fumarate accumulation leads to ‘pseudo-hypoxic’ 472 
activation of HIF-1 36, suggesting that many of the same reactions highlighted here 473 
indeed have important roles in hypoxic adaptation and, hence, survival. Our combined 474 
approach also yielded an unexpected benefit: Computational analysis was able to 475 
provide suggestions as to whether genes were under positive or negative selective 476 
pressure (an important distinction to which traditional genome-wide analytical 477 
techniques are blind). 478 
 479 
A final note regarding PFK: basic biochemistry textbooks all highlight the importance 480 
of PFK as a key regulatory step in glycolysis (e.g. page 444 in 37). Yet there is a 481 
tautology here: PFK is heavily regulated biologically (for example, by ATP/AMP, 482 
fructose 2,6-bisphosphate 37 etc.). However its heavy regulation is evidence for, not an 483 
explanation of, its importance. We note that in our simulations, using multiple 484 
objectives and alternative analytical strategies, PFK was repeatedly highlighted as 485 
being an important determinant of the objective. Our model contained no information 486 
whatsoever regarding biological regulation (for example, allosteric modulation by 487 
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other small molecules). In other words, our simulations suggest that PFK is important 488 
because it occupies a critical point in the metabolic network due to network topology 489 
and nothing more. By extension, this protein is likely to be under strong evolutionary 490 
selective pressure in many environments, leading to complex phenotypic properties. 491 
Once again this was supported in the genetic data, at least in hypoxia. 492 
 493 
Limitations 494 
Our main hypothesis - that evolution and mathematical optimization would converge 495 
on similar targets – was supported. In so doing we generated a list of genes that the 496 
two methods independently highlighted as potentially important for hypoxic survival. 497 
Although we believe that the nature of our combined approach adds additional 498 
support to the significance of these genes, we wish to stress that genes identified by 499 
any genome-wide method should be treated as ‘candidates’ only. Direct experimental 500 
evidence will always be required to clarify the function of each. Of course, for some 501 
of the genes identified by our approach, overwhelming evidence already exists 502 
confirming their importance (for example, pyruvate dehydrogenase 30, 38, 39).  503 
 504 
A second limitation relates to possible differences in the Han vs. Tibetan environment 505 
beyond simply altitude (e.g. diet and temperature). Several points are pertinent: 506 
1. Although temperatures may differ between the two locations, most very high 507 
altitude populations descend lower in winter; 508 
2. Diet may differ; however many essential elements (reliance on vegetables and use 509 
of rice) are similar; 510 
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3. Multiple studies have utilized the Han vs Tibetan genome comparison. All have 511 
found the same primary hit (EPAS1), which is a gene regulating expression of a 512 
hypoxia-responsive transcription factor;  513 
4. The candidates in the present study were chosen because computational analysis of 514 
a separate network model suggested their role in hypoxia. This makes it more likely 515 
that this was indeed the cause and is, potentially, another benefit of our approach.  516 
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Table 1: Nuclear genes encoding mitochondrial proteins: the twenty ‘most selected’ (i.e. 
smallest GWADS p-values) in Tibetan high-altitude natives  
Entrez ID Gene name GWADS min P Reaction 
5230 'PGK1' 0.000427922 'PGK' 
5211 'PFKL' 0.000562071 'PFK' 
4696 'NDUFA3' 0.001056733 'NADH2-u10m' 
34 'ACADM' 0.002100322 All ‘FAOX’ 
435 'ASL' 0.003329005 'ARGSL' 
539 'ATP5O' 0.003329005 'ATPS4m' 
27068 'PPA2' 0.004127063 'PPAm' 
2937 'GSS' 0.004425362 'GTHS' 
8170 'SLC14A2' 0.004892165 'UREAt' 
4715 'NDUFB9' 0.005012697 'NADH2-u10m' 
7991 'TUSC3' 0.005679664 'NADH2-u10m' 
3145 'HMBS' 0.006801907 'HMBS' 
10476 'ATP5H' 0.008432045 'ATPS4m' 
4709 'NDUFB3' 0.00856278 'NADH2-u10m' 
50 'ACO2' 0.008803353 'ACONTm' 
2271 'FH' 0.008830507 'FUMm' 
1350 'COX7C' 0.01011429 'CompIVr1' 
4697 'NDUFA4' 0.01011429 'NADH2-u10m' 
210 'ALAD' 0.010792961 'PPBNGS' 




Table 2: Metabolites with the largest positive shadow prices when optimising the 
mitochondrial metabolic network for either haeme or ATP synthesis (and corresponding 
reactions) 








c204(c) 1.30 C204 (1)§, C204t (1) fdp(c) 4 PFK* (1), FBA (2) 
c204coa(c) 1.30 
C204, C204CRN1 (1), 
C204CRN3 (1) 













C204 (7), C204CRN1 
(8), C204CRN3 (9) 
pheme(m) 1.00 FCLTm (6) c204crn(c) 2.00 
C204CRN1, 
C204CRN2 (10) 
ppp9(m) 1.00 PPPGOm (6), FCLTm, dhap(c) 2.00 
TPI (11), FBA, 
G3PDm (12) 
pppg9(c) 0.86 
CPPPGO (8), PPPG9tm 
(8) 
g3p(c) 2.00 
FBA, G3PATm (13), 
G3PDm, GAPD, TPI 
pppg9(m) 0.86 PPPG9tm, PPPGOm, glc-D(c) 2.00 GLCt1 (14), HEX1 

















pep(c) 1.19 PYK, CITtbm 











PGK* (16), GAPD 
(17) 









PGK*, GAPD    
§Bracketed numbers are reaction rank based on metabolite shadow price 
#Flux through this reaction was zero 




Table 3: Reactions with the smallest relative flux spans when optimising the mitochondrial 
metabolic network for either a: haeme synthesis or b: ATP synthesis 








CompIVr1* 1.2 1 ATPtm 0.01 1 
CYOR-u10m 1.2 1 CompIVr1* 0.10 2 
NADH2-u10m* 1.3 3 CYOR-u10m 0.10 3 
CPPPGO 1.4 3 SUCOASm 0.20 4 
FCLTm 1.4 3 ENO 0.21 5 
FE2t1 1.4 3 GAPD 0.21 6 
FE2tm 1.4 3 PGK* 0.21 7 
HMBS* 1.4 3 PGM 0.21 8 
PPPG9tm 1.4 3 FBA 0.21 9 
UPP3S 1.4 3 GLCt1 0.21 10 
UPPDC1 1.4 3 HEX1 0.21 11 
PPPGOm 1.4 3 PFK* 0.21 12 
5AOPtm 1.4 3 PGI 0.21 13 
AKGDm 1.4 3 TPI 0.21 14 
ALASm 1.4 3 ACONTm* 0.22 15 
ASPGLUm 1.4 3 AKGDm 0.22 16 
ASPTAm 1.4 3 CSm 0.22 17 
GLYt2r 1.4 3 ICDHxm 0.22 18 
GLYtm 1.4 3 NADH2-u10m* 0.27 19 
MDHm 1.4 3 FUMm* 0.29 20 
PPBNGS* 1.4 3    
 
#21 reactions due to ‘drawn ranking’ 
*Corresponding gene is one of the ‘twenty most selected’ in Table 1 
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Figure 1: Heatmap showing the effect of hypoxia on flux distribution in the mitochondrial metabolic network. Red = flux increased by > 0.1 U; 
green = flux decreased by > 0.1 U; yellow = flux changed by < 0.1 U..A: Flux balance analysis, with ATP synthesis as the objective function. B: 
Uniform random sampling. (U = μm min-1 g-1)




Figure 2: Biplot showing scores on principal component 1 vs. scores on principal 
component 2. Both components are from a five-component PCA model of data 
sampled in hypoxia and normoxia. Black triangles = normoxia; grey stars = hypoxia.  
 
